All news

Illumina holds 25% operating margin, targets mid-single-digit growth

Alpha Vantage · Investing.com · · AI-summarised by FinFlash

Illumina told the Jefferies Global Healthcare Conference it is on track for its growth and margin targets despite an uneven research market. The company posted a 25% operating margin in Q3 and expects similar in Q4, helped by clinical demand, NovaSeq X placements and emerging data and AI businesses.

Read original source

GEHC company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.